OMEROS CORP Payment for Debt Extinguishment or Debt Prepayment Cost
OMEROS CORP (OMER) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $11.90 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2021-03-01
- OMEROS CORP payment for debt extinguishment or debt prepayment cost for fiscal 2018 was $11.90M.
- OMEROS CORP payment for debt extinguishment or debt prepayment cost for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- OMEROS CORP payment for debt extinguishment or debt prepayment cost for fiscal 2016 was $5.70M, a 113.24% increase from fiscal 2015.
- OMEROS CORP payment for debt extinguishment or debt prepayment cost for fiscal 2015 was $2.67M, a 413.05% increase from fiscal 2014.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost | Payment for Debt Extinguishment or Debt Prepayment Cost 1 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|
| 2018-12-31 | $11.90M 10-K · filed 2021-03-01 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 | ||
| 2016-12-31 | $5.70M 10-K · filed 2019-03-01 | ||
| 2016-10-26 | $700.00K 10-K · filed 2017-03-16 | ||
| 2015-12-31 | $248.00K 10-K · filed 2017-03-16 | $2.67M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $521.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |